Document Detail

Improved myocardial perfusion in stable angina pectoris by oral lumbrokinase: a pilot study.
MedLine Citation:
PMID:  19416019     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: A novel antithrombotic agent, lumbrokinase, was evaluated in this pilot study for its efficacy in the treatment of symptomatic stable angina. DESIGN: This was a single-armed cohort study. SETTINGS: The study was conducted at the National Cardiovascular Center, Harapan Kita, Jakarta, Indonesia. SUBJECTS: The study comprised 10 patients who had coronary artery disease and stable angina and who consented to the trial. INTERVENTION: Patients were treated with oral lumbrokinase for 30 consecutive days in addition to their standard medical therapy. OUTCOME MEASURES: Stress technetium-99m sestamibi myocardial perfusion imaging (MPI) was performed before and at the conclusion of the active treatment period. The degree and extent of inducible ischemia observed on the myocardial perfusion images were evaluated using the previously validated semiquantitative indices (Summed Stress Score and Summed Difference Score). RESULTS: Following active treatment, the mean Summed Stress Score and Summed Difference Score deceased by 39% and 37%, respectively. The anginal symptom was ameliorated in 6 of 10 patients. No adverse reaction including major or minor bleeding was observed. CONCLUSIONS: This paper represents the first description of the use of oral lumbrokinase in the treatment of chronic coronary artery disease with objective assessment using MPI. Oral lumbrokinase improves regional myocardial perfusion in patients with stable angina.
Manoefris Kasim; Andrew Alexander Kiat; Mohammad Saifur Rohman; Yasmina Hanifah; Hosen Kiat
Related Documents :
11373689 - Coronary artery disease: pathogenesis and acute coronary syndromes.
11775629 - Giant hiatal hernia presenting with stable angina pectoris and syncope--a case report.
21330149 - Cardiac side effects of molecular targeted therapies: towards a better dialogue between...
12077569 - Prehospital delay in individuals with acute coronary disease: concordance of medical re...
1957549 - Silent ischaemia: an update on current concepts.
8059719 - Tissue-type plasminogen activator and plasminogen activator inhibitor activities as pre...
9327689 - Initial experience with long coronary stents: the changing practice of coronary angiopl...
12052269 - Glycoprotein receptor inhibitors in the management of acute coronary syndromes.
7691289 - Cardiac dysrhythmias during cardiovascular autonomic reflex tests.
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of alternative and complementary medicine (New York, N.Y.)     Volume:  15     ISSN:  1557-7708     ISO Abbreviation:  J Altern Complement Med     Publication Date:  2009 May 
Date Detail:
Created Date:  2009-05-19     Completed Date:  2009-07-28     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9508124     Medline TA:  J Altern Complement Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  539-44     Citation Subset:  IM    
Department of Cardiology and Vascular Medicine, Harapan Kita National Cardiovascular Center, and Faculty of Medicine, University of Indonesia, Jakarta, Indonesia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Oral
Angina Pectoris / complications,  drug therapy*
Cohort Studies
Coronary Artery Disease / drug therapy*
Endopeptidases / therapeutic use*
Fibrinolytic Agents / therapeutic use*
Middle Aged
Myocardial Perfusion Imaging / methods
Pilot Projects
Secondary Prevention / methods
Technetium Tc 99m Sestamibi / diagnostic use
Reg. No./Substance:
0/Fibrinolytic Agents; 109581-73-9/Technetium Tc 99m Sestamibi; EC 3.4.-/Endopeptidases; EC 3.4.99.-/lumbrokinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Disruption of the Ubiquitin Proteasome System following Axonal Stretch Injury Accelerates Progressio...
Next Document:  Biopolymer-based growth factor delivery for tissue repair: from natural concepts to engineered syste...